RedHill Biopharma Ltd. announced that, based on unaudited and preliminary estimates, its total net revenues for the second quarter of fiscal year 2020 were approximately $21 million, compared to $1.1 million in the first quarter of fiscal year 2020 and $1.6 million in the second quarter of fiscal year 2019, representing unaudited and preliminary estimated increases of approximately 1,900% and 1,300%, respectively. The estimated revenues for the second quarter ending June 30, 2020 reflect RedHill's current preliminary review, which is still ongoing and could result in changes to the estimated revenues figures.